JAMDA
Volume 5, Issue 1 , Pages 38-46 , January 2004

Retrospective Cohort Study of Diabetes Mellitus and Antipsychotic Treatment in a Geriatric Population in the United States

  • Peter D. Feldman, PhD

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN
    • Corresponding Author InformationAddress correspondence to Peter D. Feldman, PhD, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.
    • ,
  • Linda K. Hay, PhD

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN
    • Deceased.
    • ,
  • Walter Deberdt, MD

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN
    • ,
  • John S. Kennedy, MD

      Affiliations

    • Indiana University School of Medicine, Indianapolis, IN
    • ,
  • David S. Hutchins, MHSA

      Affiliations

    • AdvancePCS, Inc., Scottsdale, AZ
    • ,
  • Donald P. Hay, MD

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN
    • ,
  • Thomas A. Hardy, MD

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN
    • ,
  • Vicki P. Hoffmann, PharmD

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN
    • ,
  • Kenneth Hornbuckle, DVM, PhD, MPH

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN
    • ,
  • Alan Breier, MD

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN

References 

  1. Thacker S , Jones R . Neuroleptic prescribing to the community elderly in Nottingham . Int J Geriatr Psychiatry . 1997;12:833–837
  2. Ray WA , Federspiel CF , Schaffner W . A study of antipsychotic drug use in nursing homes: Epidemiological evidence suggesting misuse . Am J Public Health . 1980;70:485–491
  3. Svarstad BL , Mount JK . Nursing home resources and tranquilizer use among the institutionalized elderly . J Am Geriatr Soc . 1992;39:869–875
  4. Prien RF , Haber PA , Caffey EM . The use of psychoactive drugs in elderly patients with psychiatric disorders: Survey conducted in twelve Veterans Administration hospitals . J Am Geriatr Soc . 1975;23:104–112
  5. Segal SP , Cohen D , Marder SR . Neuroleptic medication and prescription practices with sheltered-care residents: A 12-year perspective . Am J Public Health . 1992;82:846–852
  6. Gurland BJ , Cross PS . Epidemiology of psychopathology in old age: some implications for clinical services . Psychiatr Clin North Am . 1982;5:11–26
  7. Cohen-Mansfield J , Taylor L , Werner P . Delusions and hallucinations in an adult day care population . Am J Geriatr Psychiatry . 1998;6:104–121
  8. Drevets WC , Rubin EH . Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer's type . Biol Psychiatry . 1989;25:39–48
  9. Fombonne E , Mousson F , Dassonville B , et al.   A study of prescriptions for psychotropic drugs at a French psychiatric hospital [in French] . Rev Epidemiol Sante Publique . 1989;37:29–36
  10. Garrard J , Makris L , Dunham T , et al.   Evaluation of neuroleptic drug use by nursing home elderly under proposed Medicare and Medicaid regulations . JAMA . 1991;265:463–467
  11. Auchus AP , Bissey-Black C . Pilot study of haloperidol, fluoxetine, and placebo in Alzheimer's disease . J Neuropsychiatry Clin Neurosci . 1997;9:591–593
  12. Devanand DP , Marder K , Michaels KS , et al.   A randomized, placebo-controlled dose-comparison trial of haloperidol for psychoses and disruptive behaviors in Alzheimer's disease . Am J Psychiatry . 1998;155:1512–1520
  13. Caligiuri MP , Rockwell E , Jeste DV . Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication . Am J Geriatr Psychiatry . 1998;6:75–82
  14. Caligiuri MP , Lacro JP , Jeste DV . Incidence and predictors of drug-induced Parkinsonism in older psychiatric patients treated with very low doses of neuroleptics . J Clin Psychopharmacol . 1999;19:322–328
  15. Frenchman IB , Prince T . Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances . Int Psychogeriatr . 1997;9:431–435
  16. Lindenmayer JP , Nathan AM , Smith RC . Hyperglycemia associated with the use of atypical antipsychotics . J Clin Psychiatry . 2001;62(suppl 23):30–38
  17. Wirshing DA , Spellberg BJ , Erhart SM , et al.   Novel antipsychotics and new onset diabetes . Biol Psychiatry . 1998;44:778–783
  18. Rigalleau V , Gatta B , Bonnaud S , et al.   Diabetes as a result of atypical anti-psychotic drugs—A report of three cases . Diabet Med . 2000;17:484–486
  19. Hagg S , Joelsson L , Mjörndal T , et al.   Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications . J Clin Psychiatry . 1998;59:294–299
  20. Harris MI , Flegal KM , Cowie KC , et al.   Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults . Diabetes Care . 1998;21:518–524
  21. Buse J , Cavazzoni P , Hornbuckle K , et al.   A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States . J Clin Epidemiol . 2003;56:164–170
  22. Dvirskii AA . The reciprocally modifying effect of schizophrenia and diabetes mellitus on their phenotypic manifestations [in Russian] . Tsitol Genet . 1997;31:67–70
  23. Taylor D , McConnell D , McConnell H , et al.   The Bethlem & Maudsley National Health Service Trust Prescribing Guidelines . London: Martin Dunitz; 1999;
  24. Koro CE , Fedder DO , L'Italien GJ , et al.   Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study . BMJ . 2002;325:243–247
  25. Sernyak MJ , Leslie DL , Alarcon RD , et al.   Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia . Am J Psychiatry . 2002;159:561–566
  26. Hedenmalm K , Hägg S , Ståhl M , et al.   Glucose intolerance with atypical antipsychotics . Drug Saf . 2002;25:1107–1116
  27. Keskiner A , el-Toumi A , Bousquet T . Psychotropic drugs, diabetes, and chronic mental patients . Psychosomatics . 1973;14:176–181
  28. Goldstein LE , Sporn J , Brown S , et al.   New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment . Psychosomatics . 1999;40:438–443
  29. Ober SK , Hudak R , Rusterholtz A . Hyperglycemia and olanzapine . Am J Psychiatry . 1999;156:970
  30. Bettinger TL , Mendelson SC , Dorson PG , et al.   Olanzapine-induced glucose dysregulation . Ann Pharmacother . 2000;34:865–867
  31. Domon SE , Cargile CS . Quetiapine-associated hyperglycemia and hypertriglyceridemia . J Am Acad Child Adolesc Psychiatry . 2002;41:495–496
  32. Koller EA , Doraiswamy PM . Olanzapine-associated diabetes mellitus . Pharmacotherapy . 2002;22:841–852
  33. Sobel M , Jaggers ED , Franz MA . New-onset diabetes mellitus associated with the initiation of quetiapine treatment . J Clin Psychiatry . 1999;60:556–557
  34. Lund BC , Perry PJ , Brooks JM , et al.   Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension . Arch Gen Psychiatry . 2001;58:1172–1176
  35. Newcomer JW , Haupt DW , Fucetola R , et al.   Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia . Arch Gen Psychiatry . 2002;59:337–345
  36. Melkersson K , Khan A , Hilding A , et al.   Different effects of antipsychotic drugs on insulin release in vitro . Eur Neuropsychopharmacol . 2001;11:327–332
  37. Wirshing DA , Wirshing WC , Kysar L , et al.   Novel antipsychotics: Comparison of weight gain liabilities . J Clin Psychiatry . 1999;60:358–363
  38. Allison DB , Mentore JL , Heo M , et al.   Antipsychotic-induced weight gain: A comprehensive research synthesis . Am J Psychiatry . 1999;156:1686–1696
  39. Street JS , Clark WS , Gannon KS , et al.   Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group . Arch Gen Psychiatry . 2000;57:968–976
  40. Street JS , Clark WS , Kadam DL , et al.   Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia . Int J Geriatr Psychiatry . 2001;16:S62–S70
  41. Mukherjee S , Roth SD , Sandyk R , et al.   Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance . Psychiatry Res . 1989;29:17–27
  42. Mukherjee S , Decina P , Bocola V , et al.   Diabetes mellitus in schizophrenic patients . Compr Psychiatry . 1996;37:68–73
  43. Kasanin J . The blood sugar curve in mental disease . Arch Neurol Psychiatry . 1926;16:414–419
  44. Holden RJ , Mooney PA . Schizophrenia is a diabetic brain state: An elucidation of impaired neurometabolism . Med Hypotheses . 1994;43:420–435
  45. Basson BR , Kinon BJ , Taylor CC , et al.   Factors influencing weight change in patients with schizophrenia treated with olanzapine versus haloperidol or risperidone . J Clin Psychiatry . 2001;62:231–238
  46. Luna B , Feinglos MN . Drug-induced hyperglycemia . JAMA . 2001;286:1945–1948
  47. Koller E , Schneider B , Bennett K , et al.   Clozapine-associated diabetes . Am J Med . 2001;111:716–723
  48. Koller EA, Doraiswamy PM, Cross JT. Risperidone-associated diabetes. Presented at the 84th Annual Meeting of the Endocrine Society; June 19-22, 2002; San Francisco, CA.

PII: S1525-8610(04)70042-0

JAMDA
Volume 5, Issue 1 , Pages 38-46 , January 2004

Article Tools